Answers are grounded in this paper and cite their sources.
The development of AIDS during the first year after acute infection is rare (less than 0.5% of cases) [1–3], and although cases of rapid progression to AIDS have been reported [4], the underlying factors are not well understood. Here we describe the case of an HIV-1-infected man with rapid disease progression, reaching a CD4 cell count of less than 50 cells/μl within 14 months of initial infection. An in-depth analysis of the evolution of virological and immunological characteristics in this patient identified a very weak to absent neutralizing antibody response and a significant loss of detectable HIV-1-specific CD8 T-cell responses in the absence of viral escape mutations. Case report A previously healthy 26-year-old man presented with signs of an acute HIV-1 infection syndrome [HIV enzyme-linked immunosorbent assay (ELISA) weakly positive; Western blot gp160+, p55+]. His initial plasma viral load was 314 000 HIV-1 RNA copies/ml and CD4 cell count was 726 cells/μl. His last negative HIV-1 ELISA test was in March 2002. A less-sensitive enzyme immunoassay (‘detuned ELISA’) was non-reactive, supporting a recent infection in this individual [5,6]. The study subject did not initiate antiretroviral therapy and was followed closely (Fig. 1a). Fourteen months after the initial presentation the CD4 cell count had dropped to 43 cells/μl and the viral load increased to 2.5 × 106 copies/ml. These results were confirmed 10 days later (Fig. 1a). At this time, the study subject initiated HAART (abacavir plus lamivudine and lopinavir/ritonavir).Fig. 1: Full details of study subject. (a) Longitudinal assessment of plasma viral load and CD4 cell count of the study subject, who reached a CD4 cell count of less than 50 cells/μl within 14 months, whereas the plasma viral load increased to 2.5 × 106 copies/ml. After treatment initiation with HAART the viral load went under the limit of detection and the CD4 cell count increased to 200 cells/μl. (b) IFN-γ response of CD8 T cells was assessed using intracellular cytokine staining in response to (gag, pol, nef, env, acc) at baseline, 4, 6 and 12 months after the first presentation with acute HIV-1 infection syndrome (wide bars), as well as using IFN-γ enzyme-linked immunospot and human leukocyte antigen (HLA)-matched [HLA-A2, -A68, -B14, -B44, -CW5, -CW8] optimal epitopes (narrow bars). The total responses were low and never exceeded 0.5% of CD8 T cells. The highest responses were seen against pol and the HLA-A2-restricted reverse transcriptase epitope YL9. Subdominant responses against the HLA-A68 restricted epitope QV9 in p17 or HLA-Cw8 restricted epitope in p24 TL8 never exceeded 300 spot-forming cells/million. All responses subsequently declined in the context of increasing viremia at the 6 and 12 month timepoints. (c) Neutralizing antibody titers were measured at baseline and 9 months post-infection against autologous virus, a panel of heterologous acute viruses (APV 1–20), neutralization-sensitive reference strains (NL4-3 and SF162), and a neutralization sensitive and resistant clone isolated from the same chronically infected patient (NSC and NSR, respectively). Neutralization titers are expressed as the reciprocal of the plasma dilution that inhibited virus infection by 50% (IC50). Shading indicates a neutralizing antibody titer three times greater than the negative control infection with murine leukaemia virus (aMLV) pseudotyped virus. (d) Co-receptor usage and V3 sequence alignment of selected envelope clones. Recombinant pseudotyped viral particles were produced by co-transfecting HEK293 cells with an envelope expression vector carrying the patient-derived envelope gene and an HIV genomic vector carrying a luciferase reporter gene. The resulting pseudotyped virions were used to infect U87 target cells expressing CD4 and CCR5 or CXCR4. Env clones able to to mediate the infection of CCR5-positive cells, but not CXCR4-positive cells were designated R5 tropic. Env clones able to mediate infection of both CCR5 and CXCR4-positive cells were designated R5/X4 or dual tropic. (e) Longitudinal alignment of gag and pol sequences show that no escape mutations occur at any timepoint within the targeted epitopes or the flanking regions. ABC, Abacavir; LPV/r, lopinavir/ritonavir; LTNP, long-term non-progressor; PBMC, peripheral blood mononuclear cell; SFC, spot-forming cell; 3TC, lamivudine.A superinfection with a second viral strain as a cause for the increase in viral load [7,8] was excluded by sequencing and clonal sequence analysis of gag and env genes amplified from plasma at baseline and months 9, 12, 13 and 14 post-infection. Comparison of the gag genes over the course of the study revealed that only minor sequence changes occurred, reflecting a predictable degree of natural HIV-1 evolution. Co-receptor tropism and neutralizing antibody activity of the viral envelope was investigated at baseline and at 9 months post-infection using a cell-based infectivity assay [9,10]. All clones of the env gene from the first timepoint displayed R5 tropism, but had changed by 9 months to a dual-mixed phenotype with low X4 usage (Fig. 1d). No HIV neutralizing antibody activity was detected in the patient's plasma against autologous or heterologous viruses (APV1-20) at baseline, but some activity was detected against autologous virus and reference clones (NSC/NL4-3/SF162) at 9 months post-infection (Fig. 1c). The neutralization sensitivity of the rapid progressor's virus was evaluated using plasma from a long-term non-progressor with known broadly neutralizing activity [11]. We found that the baseline virus of the rapid progressor was resistant to neutralization by plasma from the long-term non-progressor, whereas most other heterologous acute viruses tested were sensitive to neutralization by this plasma. These data suggest that the rapid progressor studied was infected with a relatively neutralization-resistant viral envelope, and may partly explain his inability to control viral replication. Virus-specific CD8 T-cell responses were assessed using flow cytometric quantification of IFN-γ production following stimulation with peptide pools of HIV-1 Gag, Pol, Nef, Env, and Acc (Vpr, Vpu, Vif, Tat, Rev) [7]. HIV-1-specific CD8 T-cell responses were highest at 4 months post-presentation, before the increase in HIV-1 replication, and the dominant HIV-specific CD8 T-cell responses were geared towards Pol followed by Gag (Fig. 1b). The dominant epitope-specific CD8 T-cell response assessed by IFN-γ enzyme-linked immunopot [7] was directed against an HLA-A2-restricted epitope in HIV-1 reverse transcriptase (YTAFTIPSI; A2–YI9) and reached 1230 spot-forming cells/106 peripheral blood mononuclear cells after 4 months of infection. Subdominant responses (< 300 spot-forming cells/106 peripheral blood mononuclear cells at 4 months) were directed against the human leukocyte antigen Cw8-restricted epitope TPQDLNTML in p24 (Cw8–TL9) and the human leukocyte antigen A68-restricted epitope QVSQNYPIV in p17 (A68–QV9). These HIV-1-specific CD8 T-cell responses subsequently declined in the context of an increasing viral load to less than 0.15% of CD8 T cells at 6 and 12 months, and responses to individual epitopes became undetectable. Interestingly, sequence analysis of the autologous virus within the targeted epitopes demonstrated that the decline in epitope-specific CD8 T-cell responses was not a consequence of viral sequence evolution, as the autologous viral sequence within the targeted epitope and flanking regions remained conserved (Fig. 1e). These data demonstrate that rapid progression in HIV-1 can be associated with both weak initial neutralizing antibody responses and the subsequent impairment of CD8-mediated antiviral activity in the absence of viral escape mutations. This report indicates that HIV-1 itself can have a strong direct impact on the dysfunction of adaptive immune responses, emphasizing the need for further research to understand mechanisms of viral immune evasion in the absence of viral sequence variation. The first two authors contributed equally to this work.
No takes yet. Share an insight, caveat, or question.
Streeck et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: